• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.03% Nasdaq Up0.17%

    Hemispherx Biopharma, Inc. (HEB)

    -NYSE MKT
    0.22 0.01(5.91%) Dec 24, 1:01PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Hemispherx Biopharma, Inc.
    One Penn Center
    1617 JFK Boulevard
    Philadelphia, PA 19103
    United States - Map
    Phone: 215-988-0080
    Fax: 215-988-1739
    Website: http://www.hemispherx.net

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:39

    Business Summary 

    Hemispherx Biopharma, Inc., a specialty pharmaceutical company, is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company products comprise Ampligen, an experimental drug, which is under clinical development for the treatment of chronic fatigue syndrome, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma. Its products also include Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza, seasonal influenza, and other emerging viruses. The company has a strategic alliance with Bioclones (Pty) Ltd. to develop various projects. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

    Key Statistics


    Company Websites 
    Home Page
    Investor Relations
    Products & Services
    Search Yahoo! for:
    More on Hemispherx Biopharma, Inc.

    Key Executives 
     PayExercised
    Dr. William A. Carter M.D., 76
    Chairman, Chief Exec. Officer, Pres, Chief Scientific Officer, Chairman of Exec. Committee, Member of Strategic Planning Committee and Member of Disclosure Controls Committee
    1.34M0.00
    Mr. Thomas K. Equels Esq., 62
    Exec. Vice Chairman, Gen. Counsel, Sec., Member of Exec. Committee, Member of Strategic Planning Committee and Member of Disclosure Controls Committee
    828.00K0.00
    Dr. David R. Strayer M.D., 68
    Chief Medical Officer and Medical Director
    291.00K0.00
    Mr. Charles T. Bernhardt CPA, M.B.A., 53
    Chief Financial Officer, Chief Accounting Officer and Member of Disclosure Controls Committee
    N/AN/A
    Mr. Richard C. Piani , 87
    Consultant
    71.00KN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders